Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Elanco Animal Health IncorporatedNYSE: ELAN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $99M rose 11.2% year over year, ahead of the +7.0% change in trailing-twelve-month research & development. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Research & development amounted to 7.8% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.2% holds above the trailing-twelve-month pace of +7.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 368M USD
- Year-over-year change
- +7.0%
- 4-year CAGR
- -0.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 368M | +7.0% |
| FY2024 | 2024-12-31 | 344M | +5.2% |
| FY2023 | 2023-12-31 | 327M | +1.9% |
| FY2022 | 2022-12-31 | 321M | -13.0% |
| FY2021 | 2021-12-31 | 369M | — |
Research & Development vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 research & development of $381M is the 3rd highest of the 6 companies compared; the peer median is $266.87M.
- Its year-over-year change of +7.0% is the 3rd highest of 5, against a peer median of +8.0%.
- Research & development amounts to 7.4% of revenue for ELAN, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B | +65.7% | -2.6% | 42.7% | |
| LTM Jun 2026 | $722M | +5.9% | +9.0% | 7.6% | |
| LTM Sep 2026 | $381M | +7.0% | +4.7% | 7.4% | |
| LTM Sep 2026 | $266.87M | +10.2% | -0.5% | 5.7% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ELAN) | $266.87M | +8.0% | -1.5% | 5.7% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.76B | 4.41B | 4.42B | 4.44B | 4.72B |
| Cost of Revenue | 2.69B | 2.44B | 2.48B | 2.53B | 2.67B |
| Gross Profit | 2.08B | 1.97B | 1.94B | 1.91B | 2.05B |
| Gross Margin | 43.6% | 44.7% | 43.9% | 43.0% | 43.5% |
| Research & Development | 369M | 321M | 327M | 344M | 368M |
| Selling, General & Admin | 1.4B | 1.27B | 1.29B | 1.31B | 1.43B |
| Operating Expenses | 1.77B | 1.59B | 1.61B | 1.66B | 1.8B |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| EBITDA | 409M | 866M | (224M) | 1.49B | 676M |
| EBITDA Margin | 8.6% | 19.6% | -5.1% | 33.5% | 14.3% |
| Operating Income | 304M | 384M | 326M | 251M | 252M |
| Operating Margin | 6.4% | 8.7% | 7.4% | 5.7% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 45M |
| Interest Expense | 264M | 256M | 277M | 339M | 220M |
| Other Income / Expenses | (875M) | (456M) | (1.52B) | 237M | (476M) |
| Income Before Tax | (571M) | (72M) | (1.2B) | 488M | (224M) |
| Pre-Tax Margin | -12.0% | -1.6% | -27.1% | 11.0% | -4.8% |
| Income Tax Expense | (88M) | 6M | 36M | 150M | 8M |
| Net Income | (483M) | (78M) | (1.23B) | 338M | (232M) |
| Net Margin | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (Basic) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| EPS (Diluted) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| Weighted Avg Shares | 487.2M | 488.3M | 492.3M | 494M | 496.4M |
| Weighted Avg Shares (Diluted) | 487.2M | 488.3M | 492.3M | 497.3M | 496.4M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.